Scientific Concept of the National Cohort (status ... - Nationale Kohorte

More documents

Recommendations

Info

C.1 C.1 Annex: Description of the study centers stitutes and independent departments, which are interlinked and cooperate on various topics and in various research programs. The center runs diverse technology platforms which function as central service units. To ensure rapid and efficient transfer of findings from basic research into medical applications, scientists of Helmholtz Center Munich work closely in translational centers and clinical cooperation groups together with medical partners in the universities and hospitals in Munich. Research at the Institute of Epidemiology at HMGU focuses on the effects of environmental factors and genetic predisposition – as well as their interaction – on human health by means of epidemiologic methods. The main research areas in terms of disease endpoints of the institute are diabetes and the metabolic syndrome, cardiovascular diseases (CVD), diseases of the respiratory system, and allergies. Exposures of interest include indoor and outdoor air pollution, ionizing radiation, diet, physical activity, and psychosocial factors. The integration of molecular epidemiologic methods has become an indispensable part of the epidemiologic research activities of the institute. The scientific output of the institute is reflected in the publication record (http://www.helmholtz-muenchen.de/epi/publikationen/uebersicht/index.html) which also demonstrates that numerous national and international collaborations are a major part of the successful scientific work. In particular, the area of genome-wide association studies (GWAS) has proven to be a very efficient source of scientific collaborations and publications, thanks to the abundant phenotypic data available in MONICA/KORA. The Institute of Epidemiology at the HMGU manages several population-based epidemiologic studies covering a broad age range, from birth to old age. The largest and most prominent study is the population-based MONICA/KORA cohort with about 18,000 subjects in the age range of 25–74 years at recruitment. Participants were enrolled during four recruitment periods in 1984/85, 1989/90, 1994/95, and 1999/2001 and were subsequently followed up for disease outcomes. Further cohort studies include two birth cohorts, the GINI study (n~6,000; recruitment 1995-98), and the LISA study (n~3,100; recruitment 1997–99), both with regular follow-up since birth. All studies include physical examinations and, with the exception of earlier study components, have incorporated the collection of biological specimens (blood, urine, faeces, and saliva). Laboratory expertise is provided by the Molecular Epidemiology Group at HMGU, headed by T. Illig. T. Illig’s lab has strong expertise in both genotyping and metabolomics. Of specific importance is the expertise in standardized collection and storage of biomaterials obtained in epidemiologic studies. Members of the HMGU group have developed a concept for long-term management of the biospecimens to be collected from the National Cohort participants. With respect to the baseline examinations, HMGU will cooperate with researchers from outside, especially from the Medical Faculties of the Universities in Munich (LMU, TUM); for magnet resonance imaging a close cooperation with M. Reiser (Institute of Radiology, LMU) has been established. Description of the study center Augsburg The region of Augsburg – consisting of the city of Augsburg and the two neighboring counties of Augsburg and Aichach-Friedberg – has a source population of 420,000 inhabitants in the age range of 20–69 years, of which 20,000 subjects shall be recruited into the National Cohort. The study center for the recruitment and follow-up of theses study participants will be located in the city of Augsburg, about 70 km west of Munich. The study center is close to the railway station and thus easy to access for the study participants (by train, bus, or car). 228
229 C.1 Annex: Description of the study centers For many years, the HMGU has been running a study center in Augsburg in which population-based studies, especially the MONICA/KORA studies, were conducted; since 2001, it has been under the supervision and management of C. Meisinger. For the recruitment and follow-up of the National Cohort, another floor (about 500 m²) in the same building will be rented. As previous studies have been carried out there, a wide experience and a functional infrastructure can be found, which will be used for the purposes of the National Cohort. Successful cooperation with medical facilities, in particular with the Augsburg Hospital (Klinikum Augsburg) will be continued to the benefit of the National Cohort. Augsburg is the only study region in Germany with the possibility of linkage to a population-based myocardial infarction (MI) registry. The MI registry, also headed by C. Meisinger, is located at the Klinikum Augsburg and has now been operational for 25 years. Table 1: Overview of participating institutions and investigators/scientists Study center Regensburg Table 3: Overview of participating institutions and investigators/scientists Institution Town Principal investigator Institute/department/division e-mail Co-principal investigator Institute/department/division e-mail Institution Town Associated scientist Institute/department/division e-mail Institution Town Associated scientist Institute/department/division e-mail Institution Town Associated scientist Institute/department/division e-mail Regensburg University (RU) 93053 Regensburg Prof. Dr. Dr. Michael Leitzmann Department of Epidemiology and Preventive Medicine Michael.Leitzmann@klinik.uni-regensburg.de Prof. Dr. Iris M. Heid Department of Epidemiology and Preventive Medicine Iris.Heid@klinik.uni-regensburg.de Regensburg University (RU) 93053 Regensburg Dr. Beate Fischer Department of Epidemiology and Preventive Medicine Beate.Fischer@klinik.uni-regensburg.de Medical Faculty of Regensburg University 93053 Regensburg Prof. Dr. Bernhard Weber Institute of Human Genetics at the University of Regensburg Bernhard.Weber@klinik.uni-regensburg.de University Hospital Regensburg 93053 Regensburg Prof. Dr. Günter Riegger Regensburg University Medical Center Guenter.Riegger@klinik.uni-regensburg.de C.1
Page 1:
The National Cohort A prospective e
Page 4 and 5:
Applicants Applicants Applicants Cl
Page 6 and 7:
Applicants IV
Page 8 and 9:
Executive Summary 2. The National C
Page 10 and 11:
Executive Summary 3. Scientific aim
Page 12 and 13:
Executive Summary essary to address
Page 14 and 15:
Executive Summary 7. Examples for s
Page 16 and 17:
Contents A.2.4 major areas of expos
Page 18 and 19:
Contents A.3.8.2 Social security da
Page 20 and 21:
Contents A.6.4.2 Minimally detectab
Page 22 and 23:
Abbreviations C.2 mEThOdS fOr STATI
Page 24 and 25:
Abbreviations DXA Dual-energy x-ray
Page 26 and 27:
Abbreviations CHS Cardiovascular He
Page 28 and 29:
A.1 A.1 Introduction and overview a
Page 30 and 31:
A.1 A.1 Introduction and overview s
Page 32 and 33:
A.1 A.1 Introduction and overview T
Page 34 and 35:
A.1 A.1 Introduction and overview m
Page 36 and 37:
A.1 A.1 Introduction and overview
Page 38 and 39:
A.1 A.1 Introduction and overview s
Page 40 and 41:
A.1 A.1 Introduction and overview
Page 42 and 43:
A.1 A.1 Introduction and overview P
Page 44 and 45:
A.1 A.1 Introduction and overview t
Page 46 and 47:
A.1 A.1 Introduction and overview A
Page 48 and 49:
A.2 A.2. Scientific background and
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
A.3 A.3 Study design ment instrumen
Page 84 and 85:
A.3 A.3 Study design Table 3.2: Des
Page 86 and 87:
A.3 A.3 Study design Table 3.3: Dis
Page 88 and 89:
A.3 A.3 Study design the participan
Page 90 and 91:
A.3 A.3 Study design with a prepare
Page 92 and 93:
A.3 A.3 Study design rural areas, t
Page 94 and 95:
A.3 A.3 Study design A.3.2 Baseline
Page 96 and 97:
A.3 A.3 Study design Modules 70 Int
Page 98 and 99:
A.3 A.3 Study design ovarian carcin
Page 100 and 101:
A.3 A.3 Study design Table 3.5: Spe
Page 102 and 103:
A.3 A.3 Study design depression and
Page 104 and 105:
A.3 A.3 Study design to the extent
Page 106 and 107:
A.3 A.3 Study design ers to vaccina
Page 108 and 109:
A.3 A.3 Study design certain foods)
Page 110 and 111:
A.3 A.3 Study design A short instru
Page 112 and 113:
A.3 A.3 Study design ticipants and
Page 114 and 115:
A.3 A.3 Study design a resting time
Page 116 and 117:
A.3 A.3 Study design index, convent
Page 118 and 119:
A.3 A.3 Study design Although the i
Page 120 and 121:
A.3 A.3 Study design air and then t
Page 122 and 123:
A.3 A.3 Study design hemorrhages (0
Page 124 and 125:
A.3 A.3 Study design genetics of BM
Page 126 and 127:
A.3 A.3 Study design hand grip stre
Page 128 and 129:
A.3 A.3 Study design Project title
Page 130 and 131:
A.3 A.3 Study design diseases in va
Page 132 and 133:
A.3 A.3 Study design associations,
Page 134 and 135:
A.3 A.3 Study design Informed Conse
Page 136 and 137:
A.3 A.3 Study design 6. Since being
Page 138 and 139:
A.3 A.3 Study design the possible d
Page 140 and 141:
A.3 A.3 Study design A.3.5 Collecti
Page 142 and 143:
A.3 A.3 Study design Blood In addit
Page 144 and 145:
A.3 A.3 Study design the anterior n
Page 146 and 147:
A.3 A.3 Study design study. For exa
Page 148 and 149:
A.3 A.3 Study design large-size sto
Page 150 and 151:
A.3 A.3 Study design routinely prep
Page 152 and 153:
A.3 A.3 Study design Subjects who m
Page 154 and 155:
A.3 A.3 Study design A.3.6.3 reliab
Page 156 and 157:
A.3 A.3 Study design In addition, a
Page 158 and 159:
A.3 A.3 Study design Disease Questi
Page 160 and 161:
A.3 A.3 Study design Data routinely
Page 162 and 163:
A.3 A.3 Study design tial misclassi
Page 164 and 165:
A.3 A.3 Study design � The KORA c
Page 166 and 167:
A.3 A.3 Study design Table 3.16: Co
Page 168 and 169:
A.3 A.3 Study design Table 3.17: Co
Page 170 and 171:
A.4 A.4 Integrated Data Management
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
A.5 A.5 Methods for quality assuran
Page 184 and 185:
A.5 A.5 Methods for quality assuran
Page 186 and 187: A.5 A.5 Methods for quality assuran
Page 196 and 197: A.6 A.6 Planned statistical analyse
Page 204 and 205: A.6 A.6 Table Planned 6.4: Expected
Page 208 and 209: A.6 Planned statistical analyses an
Page 218 and 219: A.7 A.7 Ethical aspects logical/gen
Page 220 and 221: A.7 A.7 Ethical aspects The more ex
Page 222 and 223: A.7 A.7 Ethical aspects pants, trav
Page 224 and 225: A.7 A.7 Ethical aspects Data handli
Page 226 and 227: A.7 Table 7.2 Availability of ident
Page 228 and 229: A.7 A.7 Ethical aspects Should bios
Page 230 and 231: A.7 A.7 Ethical aspects ing finding
Page 232 and 233: A.7 A.7 Ethical aspects 206
Page 234 and 235: C.1 C.1 Annex: Description of the s
Page 258 and 259: C.1 C.1 Table Annex: 1: Cluster Des
Page 282 and 283: C.2 C.2 Annex: Methods for Statisti
Page 284 and 285: C.2 C.2 Annex: Methods for Statisti
Page 286 and 287:
C.2 Table S6.5: Sample size needed
Page 288 and 289:
C.2 C.2 Annex: Methods for Statisti
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
C.3 References 17. Keil, U., et al.
Page 298 and 299:
C.3 References 50. Benjamin, E.J.,
Page 300 and 301:
C.3 References 85. Calle, E.E. and
Page 302 and 303:
C.3 References 121. Walter, R., D.J
Page 304 and 305:
C.3 References 155. Ross, R., Ather
Page 306 and 307:
C.3 References 189. Ghiotto, F., et
Page 308 and 309:
C.3 References 225. Schmidt, C.O.,
Page 310 and 311:
C.3 References 260. Eussen, S., et
Page 312 and 313:
C.3 References 294. McCrae, R.R. an
Page 314 and 315:
C.3 References 327. Lynch, J.W., G.
Page 316 and 317:
C.3 References 360. Mair, C., A.V.
Page 318 and 319:
C.3 References 395. Lesourd, B., Nu
Page 320 and 321:
C.3 References 431. Statistisches B
Page 322 and 323:
C.3 References 462. Bundeszentrale
Page 324 and 325:
C.3 References 494. Rammstedt, B. a
Page 326 and 327:
C.3 References 526. Mack, F., et al
Page 328 and 329:
C.3 References 560. Palatini, P., A
Page 330 and 331:
C.3 References 590. Greenland, P.,
Page 332 and 333:
C.3 References 623. Olin, A.C., et
Page 334 and 335:
C.3 References 658. Pate, R.R., J.R
Page 336 and 337:
C.3 References 691. Zenge, M.O., et
Page 338 and 339:
C.3 References 727. Ryu, O.H., et a
Page 340 and 341:
C.3 References 757. BSI-Standard 10
Page 342 and 343:
C.3 References 790. Davis, C.E., et
Page 344:
C.3 References 822. Hegenscheid, K.
show all

Scientific Concept of the National Cohort (status ... - Nationale Kohorte

Create successful ePaper yourself

Delete template?

Save as template?